phosphoribosyl-n-formylglycineamide has been researched along with Benign Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alt, J | 1 |
| Gori, SS | 1 |
| Lemberg, KM | 1 |
| Pal, A | 1 |
| Veeravalli, V | 1 |
| Wu, Y | 1 |
| Aguilar, JMH | 1 |
| Dash, RP | 1 |
| Tenora, L | 1 |
| Majer, P | 1 |
| Sun, Q | 1 |
| Slusher, BS | 1 |
| Rais, R | 1 |
1 other study available for phosphoribosyl-n-formylglycineamide and Benign Neoplasms
| Article | Year |
|---|---|
Glutamine Antagonist GA-607 Causes a Dramatic Accumulation of FGAR which can be used to Monitor Target Engagement.
Topics: Animals; Biomarkers, Pharmacological; Biomarkers, Tumor; Chromatography, Liquid; Drug Development; G | 2021 |